The San Antonio Breast Cancer Symposium is attended by academic and private researchers and physicians from around the world providing a balance of clinical, translational, and basic research, for those with a special interest in breast cancer.
I-SPY2 Supports Neoadjuvant Cemiplimab/REGN3767 in Early-Stage, High-Risk Breast Cancer
December 10th 2022The ongoing multicenter open-label adaptively randomized phase 2 I-SPY2 trial is currently investigating dual immune blockade with cemiplimab plus the investigational agent REGN3767 as neoadjuvant therapy for early-stage, high-risk breast cancer, and new data were presented yesterday at the San Antonio Breast Cancer Symposium.
Read More
10-Year Babytam Data Show Reduced-Dose Tamoxifen Still Producing Positive Results
December 9th 2022Babytam is the 5-mg daily dose of tamoxifen being studied in the ongoing TAM-01 study, which is investigating incidence of invasive breast cancer or ductal carcinoma in situ among high-risk women who have received the treatment regimen for 3 years.
Read More
Dr Lola Fayanju Shares How Providers Can Leverage PROs to Improve Breast Cancer Care
December 9th 2022Patient-reported outcomes (PROs) within breast cancer settings can be instrumental in helping patients feel heard and improving their overall quality of care, said Oluwadamilola "Lola" Fayanju, MD, MA, MPHS, FACS, chief of breast surgery at Penn Medicine.
Read More
Dr William Jacout Offers Advice for Providers Using Genomics to Inform Breast Cancer Treatment
December 9th 2022William Jacout, MD, a medical oncologist and researcher at the Institut du Cancer de Montpellier Val d'Aurelle in France, shares what providers should keep in mind when using genomics as a diagnostic and treatment decision-making tool for patients with breast cancer.
Read More
Optimizing Screening MRI for Women With High Risk of Breast Cancer
December 9th 2022The utility of annual MRI plus mammogram was investigated in a new meta-analysis delivered at this year’s San Antonio Breast Cancer Symposium, with the goal of optimizing use of MRI by considering potential for overdiagnosis and tailoring to age and risk group.
Read More
Dr Adam Brufsky Describes the Evolution of Treatment Options for HER2-Low Breast Cancer
December 8th 2022Human epidermal growth factor receptor 2 (HER2)-low breast disease has a number of new treatments available, and more providers need to be aware of how it differs from other forms of breast cancer, according to Adam Brufsky, MD, PhD, University of Pittsburgh, at the San Antonio Breast Cancer Symposium.
Read More
New Research Highlights Clinical Significance of HER2-Low Breast Disease
December 8th 2022With human epidermal growth factor receptor 2 (HER2)–low breast cancer still a relatively newly classified disease subtype, research is increasingly focused on the disease, in which cells express lower levels of the HER2 protein than are adequate to classify a patient as having HER2-positive disease.
Read More
Dr Jose P. Leone Highlights the Importance of Breast Cancer Awareness for Male Patients
December 8th 2022Jose P. Leone, MD, director of the program for breast cancer in men at the Dana-Farber Cancer Institute and assistant professor of medicine at Harvard Medical School, shares why patients and providers need to pay more attention to how breast cancer impacts male patients.
Read More
DESTINY-Breast Data Add to Accolades for Trastuzumab Deruxtecan
December 7th 2022A highlight of day 2 at the San Antonio Breast Cancer Symposium was the morning presentation of a pair of studies highlighting the ongoing survival benefit associated with trastuzumab deruxtecan in metastatic breast cancer.
Read More
Dr Dawn Hershman Discusses Tactics to Increase Drug Adherence in Clinical Trials
December 7th 2022Dawn L. Hershman, MD, an oncologist from Columbia University, shared insight into the current challenge of ensuring drug adherence within clinical trials and how this adherence can impact the quality of care for patients in real-world settings.
Read More
Dr Irene Kang Shares Cognitive Impairment Results From the RxPonder Breast Cancer Study
December 7th 2022Irene M. Kang, MD, from City of Hope, shared some of the results from her analysis of cognitive impairment in women with breast cancer who participated in the RxPonder study, which assessed which patients would benefit most from chemotherapy.
Read More
Financial Toxicity From Cancer Is a Patient-Facing Problem, MSK’s Chino States
December 6th 2022Costs are an adverse effect of treatment just like any other adverse effect, with slightly more patients worried about the financial impact of their cancer diagnosis than they are about actually dying from their disease, noted Fumiko Chino, MD, of Memorial Sloan Kettering (MSK) Cancer Center.
Read More
Dr Neil Iyengar Previews SABCS Presentation on Metabolic Dysregulation in Breast Cancer
December 5th 2022Neil Iyengar, MD, from Memorial Sloan Kettering Cancer Center, is expecting updates on therapies to fight human epidermal growth factor 2 (HER2)–positive breast cancer and novel antibody drug conjugates at the upcoming San Antonio Breast Cancer Symposium (SABCS).
Read More
High-risk Disease, Novel Treatments, Health Care Equity Highlighted at SABCS
December 4th 2022The annual San Antonio Breast Cancer Symposium (SABCS) will once again take place in a hybrid fashion, with in-person attendees returning to the Henry B. Gonzales Convention Center to hear the latest clinical and basic research, as well as see several of their peers receive awards for their contributions to the space.
Read More
Investigators Initiate Post-Trastuzumab Trial of GLSI-100 in Patients With Invasive Breast Cancer
December 7th 2021Investigators hope to duplicate promising phase 2b trial results with an experimental peptide vaccine in a population of nearly 500 patients with human epidermal growth factor receptor 2 breast cancer.
Read More
Dr Funmi Olopade Previews Her Keynote Address for SABCS
December 6th 2021Funmi Olopade, MD, FACP, professor of medicine and human genetics and founding director of the Center for Clinical Cancer Genetics and Global Health at the University of Chicago Medical Center, previews her keynote address for the San Antonio Breast Cancer Symposium (SABCS).
Read More
Dr Hope Rugo on the Importance of a Potential Oral Paclitaxel Option in Metastatic Breast Cancer
December 11th 2020Hope Rugo, MD, director of Breast Oncology and Clinical Trials Education at the UCSF Helen Diller Family Comprehensive Cancer Center, discusses the benefits of oral paclitaxel in metastatic breast cancer.
Read More
Dr Lee Schwartzberg Discusses Immunotherapy Approvals in TNBC
December 10th 2020Lee Schwartzberg, MD, FACP, chief medical director of West Cancer Center and chief medical officer of OneOncology, discusses the approvals of pembrolizumab and sacituzumab govitecan for patients with triple-negative breast cancer.
Read More
A Look at Established, Emerging Biomarkers for I-O Therapy in Breast Cancer
December 10th 2020During the San Antonio Breast Cancer Symposium 2020, Lajos Pusztai, MD, DPhil, of Yale Cancer Center, reviewed recently established and emerging biomarkers in both the neoadjuvant and metastatic breast cancer settings.
Read More
Dr Banu Arun on Technologies to Expand Access to Genetic Counseling
December 15th 2019There are new technologies that allow for genetic counseling services through which the provider does not even need to get that involved in the process, said Banu Arun, MD, medical oncologist, Department of Breast Medical Oncology, Division of Cancer Medicine, MD Anderson Cancer Center.
Read More